You are here

  • Home
  • Archive
  • Volume 10, Issue 5
  • Cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) for chronic insomnia disorder (‘CANSLEEP’ trial): protocol for a randomised, placebo-controlled, double-blinded, proof-of-concept trial

Citation Tools

Article menu

Download PDFPDF

XML
Pharmacology and therapeutics
Protocol
Cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) for chronic insomnia disorder (‘CANSLEEP’ trial): protocol for a randomised, placebo-controlled, double-blinded, proof-of-concept trial

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Suraev A, Grunstein RR, Marshall NS, et al
Cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) for chronic insomnia disorder (‘CANSLEEP’ trial): protocol for a randomised, placebo-controlled, double-blinded, proof-of-concept trial
BMJ Open 2020;10:e034421. doi: 10.1136/bmjopen-2019-034421